A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited ...

John Burke, MD, discusses his editor-in-chief column from the July 2025 issue of Targeted Therapies in Oncology.

Verastem Oncology's VS-7375 receives FDA fast track designation, offering hope for targeted treatment in KRAS G12D-mutated ...

Benjamin Schlechter, MD, discusses the safety and efficacy findings from the C-800-01 phase 1 trial evaluating botensilimab ...

A recent study characterized the expression of ADC targets across ovarian cancer histotypes. Findings suggest ...

Unpredictable FDA and funding woes delay crucial drug approvals, depriving thousands of patients access to vital treatments ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Mariam Eskander, MD, explores how food insecurity and geographic barriers hinder breast cancer trial participation, ...

John M. Burke, MD, discusses the FDA ODAC's decision on the use of daratumumab in high-risk smoldering multiple myeloma and ...

The EU approves belantamab mafodotin combinations, enhancing treatment options for relapsed multiple myeloma patients with ...

Zydus Lifesciences gains FDA tentative approval for generic ibrutinib, enhancing access to vital cancer treatment for ...

During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.